Keyword: Regeneron Pharmaceuticals
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.
Regeneron and Sanofi’s PD-1 candidate cemiplimab will be tested alongside a human papillomavirus (HPV) targeting drug from Dutch biotech ISA Pharma.
Sanofi and Regeneron have touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
Decibel forged an alliance with Regeneron that lets it access the big biotech’s scientific expertise without losing rights to its drug candidates.
The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea.
After posting positive results from a midstage test of its oral immunotherapy AR101 last spring, Aimmune Therapeutics will try out its peanut allergy medication in combination with Sanofi/Regeneron’s Dupixent (dupilumab).
J&J is now assessing what it will take to quell the FDA’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward.
In a phase 2 atopic dermatitis trial, Eli Lilly and Incyte's baricitinib hit its primary endpoint but missed a secondary objective.
AbbVie has chalked up positive phase 2b data for its JAK1 inhibitor upadacitinib, setting up a late-stage program and a potential challenge to Sanofi and Regeneron's Dupixent in the evolving atopic dermatitis market.